CNS Drug Discoveries: Depression Chapter

Table of Contents

DEPRESSION

• EXECUTIVE SUMMARY
• THE FACTS
  • What is depression and why are we interested in it?
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • Summary of patient population forecasts in seven major markets (2005A-2012E)
  • Model assumptions
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS
• GLOBAL ANTIDEPRESSANT MARKET
  • Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • Global sales by region (2005A)
  • US market
    • Antidepressant US drugs sales by (2005A)
  • European market
    • European Antidepressant sales by (2005A)
  • ROW/Japanese market
  • The Major Players Products in 2005 & 2006
    • Market share of Antidepressant players by sales (Dec 2005A)
  • The Major Players and Products in 2012
    • Market share of Antidepressant Players by sales (Dec 2012E)
• CURRENT TREATMENTS
  • Leading Brands
    • Comparison of leading antidepressant drugs
  • Patent Exposure of Current Products
    • Patent Exposure of Leading Antidepressant Brands
• ANALYSIS OF LEADING BRANDS
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Lexapro/Cipralex (Forest/Lundbeck)
    • Prozac (Eli Lilly)
    • Zoloft (Pfizer)
  • Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)
    • Cymbalta (Eli Lilly)
    • Effexor (Wyeth)
  • Noradrenaline and Dopamine Reuptake Inhibitors (NDRIs)
    • Wellbutrin (GlaxoSmithKline)
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading Antidepressant Drugs
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat Depression and Anxiety Related Disorders
• ANALYSIS OF PHASE III DRUGS
  • New Drugs in Phase III Development to Treat Depression and Anxiety
  • Phase III drugs
  • Other Phase III drugs of interest